// App-Quantinova.ai

CT170 : Phase 1 study to characterize the pharmacokinetics and safety of tazemetostat in b-cell lymphomas or advanced solid tumors

Researchers

Presenter

  • Evren Kocabas Argon

Principal Investigators

  • Felicia Nguyen

  • Anand Rajarethinam

  • Vikram Kansra

  • Andrew Pettitt

Medical Centers

  • Epizyme, Cambridge, MA

  • University of Liverpool, Liverpool, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Enhancer of zeste homolog 2

  • Tafazzin

Drug/Treatment

  • Tazemetostat

  • EZH2

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

Phase

  • I

Study Id's

  • NCT03010982

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved